Multi-targeting of K-Ras domains and mutations by peptide and small molecule inhibitors
Fig 7
MTT assay and quantitative real-time PCR results.
(A) Assessment of the cell viability of AsPC-1 (up) and MIA PaCa-2 (down) cells after treatment with different concentrations of Retro-LfcinB peptide and Zinc12502230 small molecule. Values were normalized with untreated cells. The highest cytotoxicity of the compounds (at 150μM of peptide: 150μM of the small molecule) was significantly different from untreated control at P < 0.005 and P < 0.01 (Student’s t-test) in AsPC-1 and MIA PaCa-2 cells, respectively. UT: untreated cells. (B) Cancer cells expressing K-RasG12D were treated with the combination of 150μM of modified Retro-LfcinB peptide and 150μM of Zinc12502230 small molecule during 72 h, and then mRNA level was analyzed with quantitative real-time PCR for expression of K-Ras down-stream genes including CTNNB1 and CCND1. Results are the mean ± SE of three separate experiments.